Aralez Pharmaceuticals Inc. (ARLZ) Scheduled to Post Quarterly Earnings on Thursday

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) will issue its quarterly earnings data before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.01). Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The firm had revenue of $27.62 million for the quarter, compared to analyst estimates of $21.37 million. During the same period in the prior year, the firm posted ($0.27) EPS. The business’s revenue was up 119.6% compared to the same quarter last year. On average, analysts expect Aralez Pharmaceuticals to post $-1.6 EPS for the current fiscal year and $-1.12 EPS for the next fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at

Separately, Chardan Capital dropped their price objective on Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a report on Thursday, August 10th.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Earnings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply